

#### OTCQB: DFCO

# Q2 2024 Earnings Presentation



## **Company Overview**

Dalrada drives innovation that positively impacts people, businesses, and the planet. The company owns and operates a global group of health care, clean energy, precision manufacturing, and technology companies that identify, address, and deliver solutions to economic, environmental, and efficiency problems facing the public, government, and private sectors.

# **Genefic**

Genefic delivers an exciting core of frontline health products and services that meet the world's demands of today and tomorrow. Dedicated to creating improved health outcomes through redesigned systems and reimagined patient care, **Genefic** offers total health solutions through distinctive offerings.



**Dalrada Climate Technology (DCT)** is revolutionizing the global clean energy industry through state-of-the-art products—like heat pumps—that help build a sustainable energy future. DCT's unique solutions reduce energy consumption and minimize carbon footprints, increase operational efficiencies, and lower energy costs for clients around the world.







**Dalrada Precision Manufacturing** (DPM) meets today's critical manufacturing needs and provides highquality parts and components solutions. Additionally, DPM improves time-tomarket capabilities and solves the world's biggest manufacturing and supply chain challenges as a specialized service provider committed to delivering improved efficiencies.

**Dalrada Technologies** is a proud creator of digital engineering that eclipses standard capabilities. Through nextgeneration B2B and B2C digital products and services, **Dalrada Technologies** connects the world through cutting-edge software programming, modernized applications, and robust IT products specifically tailored for the digital age.







. . . . . .


MM Start

# Genefic

Total: \$11.1 million

# Fiscal Year 2024 **Revenue Breakdown**









# Q2 2024 **Financial Highlights**



### **TOTAL COST OF REVENUE:** \$4.1 million



TOTAL CONSOLIDATED SALES, GENERAL, AND **ADMINISTRATIVE COSTS:** 

\$6.2 million



TOTAL CONSOLIDATED LOSS OF OPERATIONS:

\$4.2 million



LOSS PER SHARE (EPS): \$ .06

2.5

4.5

4

3.5

3

1.5

2 —


1

0.5

0



#### **TOTAL CONSOLIDATED REVENUE:**





### **Dalrada Climate Technology Heat Pump** (DCT ONE Series)

#### State-of-the-art climate technology that combines unrivaled energy efficiency with an extremely low environmental impact.

Internationally-recognized heat pump solution that supports global Net Zero initiatives. ✓ U.S. General Services Administration & Department of Energy-identified "green building technology."

The **Dalrada's commercial heat pump** is the **only** CO2–based heat pump that delivers simultaneous heating and cooling without combustion or the burning of fossil fuels. It's the perfect replacement for outdated and inefficient water heaters, steam boilers, chillers, and cooling towers.

#### Why DCT ONE Series?

- Long-Term Cost Savings: lower energy bills through reduced consumption.
- Increased Energy Efficiency: advanced technology and climate-agnostic design.
- Comfort and Convenience: better temperature control with real-time reporting.
- Less Environmental Impact: lower emissions and reduced carbon footprint.
- Rebates and Incentives: increased eligibility for reduced overall costs.

#### Signed, Sealed, (almost) Delivered:

Dalrada Climate Technology has secured a backlog of international contracts worth approximately **\$900 million**:

- ✓ **2,300**-heat pump contract with JBS Consulting, a Paris-based distributor (5-year contract length).
- ✓ 4,500-heat pump contract with Crown Glory Holding, a Morocco-based global distributor (7-year contract length).

# Climate Technology

# **DECARBONIZING SOLUTIONS Cost-Effective** Heating & Cooling

#### **DCT ONE Series** by the Numbers:

- $\checkmark$  Up to 7 times more efficient than traditional systems
- ✓ Up to 75% reduced energy consumption
- $\checkmark$  Up to 60– 80% energy savings



|   |   |   | - |
|---|---|---|---|
|   | = | - |   |
|   |   |   |   |
|   |   |   |   |
| ē |   |   |   |

#### **Genefic Specialty Pharmacy**

#### Enhanced patient support through prescriptions, medical education, advocacy, and increased transparency.

**Genefic Specialty Pharmacy** offers a pharmacy experience like no other: a nationallyrecognized and certified local pharmacy with a global reach, delivering modern services for a busy world. As a full-service provider, they are redefining personalized healthcare in a way that's educational and transparent for patients and medical staff alike.

In addition to basic pharmacy services, **Genefic Specialty Pharmacy** provides enhanced prescription management, comprehensive and ongoing wellness education, and complete medical assistance for a variety of health conditions.

#### **Expanded Service Offerings:**

- Medical condition education
- Diabetes care
- Durable medical equipment (DME)
- Health screenings
- Home delivery
- Immunizations
- Medication therapy
- Wellness classes

#### **Core Values:**

- Advocate on behalf of patients
- Facilitate patient education
- Improve patient lives daily
- Create transparency between patients and staff
- Employ highly-trained, ethical pharmacists and technicians



Redefining the modern pharmaceutical experience.



#### **Dalrada Precision Manufacturing**

#### Meeting the critical quality of today's advanced machining and manufacturing needs for global industries.

**Dalrada Precision Manufacturing** responds to consumer challenges with in-house design, engineering, and distribution through an efficient supply chain and improved time-to-market capabilities.

The subsidiary exceeds the standard of quality of today's advanced products in a variety of industries, including semiconductors, automotive, aviation, biotechnology, pharmaceuticals, and clean energy.

- OEM & custom precision parts
- Clean energy technology & machinery
- Semiconductor & microchip technology
- Industrial-strength cleaners & degreasers

#### **Key Components**

- Design and development
- In-house solutions
- Global supply chain
- Engineering excellence



A total end-to-end manufacturing solution delivering high-quality components.



### **Dalrada Technologies**

#### Next-generation digital products and services that connect the world through integrated technological solutions.

**Dalrada** creates a suite of B2B and B2C solutions through a global development team of technology and digital engineering experts.

With hyper-personalized, web 3.0 solutions that eclipse standard digital engineering capabilities, **Dalrada** offers advanced software programming, modernized applications, and robust IT products and services specifically tailored for the digital age.

#### **Future-Facing Science**

- Software engineering and testing
- Application modernization
- Advanced digital ecosystems
- Digital twinning and machine learning
- Artificial intelligence
- Metaverse and virtual reality

#### **Modern Results**

- Better user experiences
- Increased data security
- Improved accuracy
- Safer digital experiences
- Inclusive environments
- Efficient communications

Digital engineering that transcends traditional capabilities.



# Metrics – Q2 vs. Q1 2024

Revenue Increase \$1.1 million increase of 21.1%

#### Q2 2024 OVER Q1 2024 HIGHLIGHTS:

**GROSS MARGIN** 


+106.2%


SALES, GENERAL, AND ADMINISTRATIVE EXPENSES \* +5.6%


**OPERATING LOSS \*** 


-19.1%


\* Excludes stock-based compensation of \$1,018,827 and \$1,109,642 for the three months ended December 31, 2023 and September 30, 2023, respectively.














## Dalrada Revenue (Fiscal 2021-2024)








# **Unaudited Consolidated Statements of Operations**

|  | Three Months EndedSix Months EndedDecember 31,December 31, |             | d       |           |         |                      |         |           |
|--|--|-------------|---------|-----------|---------|----------------------|---------|-----------|
|  |  | 2023        |         | 2022      | 2       | 2023                 |         | 2022      |
| Revenues   | \$   | 5,859,240   |         | ,603,878  |         | ,980,866             |         | 776,127   |
| Revenues - related party   |  | 218,522     |         | 649,242   | ,       | ,114,976             | ,       | 734,760   |
| Total revenues   | -  | 6,077,762   | 5       | ,253,120  | 11,     | ,095,842             | 9,      | 510,887   |
| Cost of revenues   |  | 4,076,002   | 2       | ,955,132  | 8,      | ,123,224             | 5,      | 311,460   |
| Gross profit   |  | 2,001,760   | 2       | ,297,988  | 2,      | ,972,618             | 4,      | 199,427   |
| Operating expenses:  |  |             |         |           |         |                      |         |           |
| Selling, general and administrative (includes stock-based compensation of \$1,018,827 and \$901,721 for the three months and | l  |             |         |           |         |                      |         |           |
| \$2,128,469 and \$1,369,238 for the six months ended 2023 and  |  |             |         |           |         |                      |         |           |
| 2022, respectively)  |  | 6,227,434   | 7.      | ,080,077  | 12,     | ,270,088             | 11,     | 937,694   |
| Total operating expenses   |  | 6,227,434   |         | ,080,077  |         | ,270,088             |         | 937,694   |
| Loss from operations   |  | (4,225,674) | (4      | ,782,089) | (9,     | ,297,470)            | (7,     | 738,267)  |
| Other income (expense):  |  |             |         |           |         |                      |         |           |
| Interest expense   |  | (213,960)   | (1      | ,220,603) | (       | (327,153)            | (1,     | 892,730)  |
| Interest income  |  | 20,884      |         | 22,826    |         | 40,127               |         | 41,895    |
| Other income   |  | (1,023,079) | (       | (444,699) | (       | (688,699)            | (       | 106,622)  |
| Gain on expiration of accrued tax liability  |  | -           | 2       | ,037,712  |         | -                    | 2,      | 090,978   |
| Gain (loss) on foreign exchange  |  | 1,649       |         | (95,312)  |         | (5,121)              |         | (47,595)  |
| Total other income (expense), net  |  | (1,214,506) |         | 299,924   | (       | (980,846)            |         | 85,926    |
| Loss before taxes  |  | (5,440,180) | (4      | ,482,165) | (10,    | ,278,316)            | (7,     | 652,341)  |
| Income taxes   | _  | -           |         | -         |         | -                    |         | -         |
| Net loss   |  | (5,440,180) | (4      | ,482,165) | (10,    | ,278,316)            | (7,     | 652,341)  |
| Other comprehensive loss   |  |             |         |           |         |                      |         |           |
| Foreign currency translation   |  | (39,026)    |         | (34,129)  |         | 46,182               |         | 29,633    |
| Comprehensive loss   | \$   | (5,479,206) | \$ (4   | ,516,294) | \$(10,  | ,232,134)            | \$ (7,  | 622,708)  |
| Net income (loss) attributable to noncontrolling interests   |  | (33,982)    |         | (69,147)  |         | (55,876)             |         | 378,466   |
| Net loss attributable to Dalrada Financial Corporation stockholders  | \$   | (5,406,198) | \$ (4   | ,413,018) | \$(10,  | ,222,440)            | \$ (8,  | 030,807)  |
| Net loss per common share to Dalrada stockholders - basic  | \$   | (0.06)      | \$      | (0.05)    | \$      | (0.11)               | \$      | (0.10)    |
| •  | ♪<br>\$  |             | ъ<br>\$ |           | ֆ<br>\$ |                      | ֆ<br>\$ | · · · · · |
| Net loss per common share to Dalrada stockholders - diluted  | Φ  | (0.06)      | Φ       | (0.05)    | Φ       | (0.11)               | Φ       | (0.10)    |
| Weighted average common shares outstanding — basic   |  | 89,962,164  | 84      | ,437,801  | 89,     | ,120,328             | 80,     | 721,783   |
| Weighted average common shares outstanding — diluted   |  | 89,962,164  |         | ,437,801  |         | ,120,328             |         | ,721,783  |
|  |  |             |         | ,,        |         | ,- <b></b> , <b></b> |         | 1,700     |



## **Unaudited Consolidated Balance Sheet**

|   | December 31, 2023  | June 30,<br>2023  |  |  |
|---|--|---|--|--|
| Assets  | (Unaudited)  |   |  |  |
| Current assets:   |  |   |  |  |
| Cash and cash equivalents   | \$ 598,438   | \$ 812,806  |  |  |
| Accounts receivable, net  | 5,488,915  | 4,453,104   |  |  |
| Accounts receivable, net - related parties  | 928,648  | 752,348   |  |  |
| Other receivables   | 1,240,009  | 376,604   |  |  |
| Inventories   | 2,569,843  | 2,078,692   |  |  |
| Prepaid expenses and other current assets   | 668,877  | 1,343,491   |  |  |
| Total current assets  | 11,494,730   | 9,817,045   |  |  |
| Long-term receivables   | 20,141   | 41,722  |  |  |
| Long-term receivables - related parties   | 1,155,479  | 1,173,893   |  |  |
| Property and equipment, net   | 1,623,011  | 1,476,082   |  |  |
| Goodwill  | 3,803,147  | 3,803,147   |  |  |
| Intangible assets, net  | 3,654,823  | 3,858,086   |  |  |
| Right-of-use asset, net   | 2,714,198  | 2,771,854   |  |  |
| Right-of-use asset, net - related party   | 1,960,494  | 2,227,286   |  |  |
| Total assets  | \$ 26,426,023  | \$ 25,169,115   |  |  |
| 10141 455015  | \$ 20,420,025  | \$ 25,109,115   |  |  |
| Liabilities and Stockholders' Equity  |  |   |  |  |
| Current liabilities:  |  |   |  |  |
| Accounts payable  | \$ 5,554,117   | \$ 5,178,897  |  |  |
| Accrued liabilities   | \$ 5,554,117<br>920,159  | 1,084,008   |  |  |
|   |  | 547,949   |  |  |
| Accounts payable and accrued liabilities – related parties<br>Deferred revenue  | 5,029,683  | ,   |  |  |
|   | 938,823  | 1,337,259   |  |  |
| Notes payable, current portion  | 439,562  | 439,562   |  |  |
| Notes payable, current portion – related parties  | -  | 251,605   |  |  |
| Right-of-use liability  | 757,569  | 660,394   |  |  |
| Right-of-use liability - related party  | 536,265  | 519,791   |  |  |
| Total current liabilities   | 14,176,178   | 10,019,465  |  |  |
| Long-term payables  | 33,893   | 48,888  |  |  |
| Notes payable   | 2,414,936  | 1,011,395   |  |  |
| Notes payable – related parties   | 4,834,971  | 1,648,478   |  |  |
| Contingent consideration  | 4,402,394  | 4,285,389   |  |  |
| Right-of-use liability  | 2,027,911  | 2,160,834   |  |  |
| Right-of-use liability - related party  | 1,467,407  | 1,741,830   |  |  |
| Total liabilities   | 29,357,690   | 20,916,279  |  |  |
| Commitments and contingencies (Note 14)   |  |   |  |  |
| Stockholders' equity:   |  |   |  |  |
| Stockholder's equity:<br>Series I preferred stock, \$0.01 par value, 100,000 shares authorized, 35,108 shares issued and  |  |   |  |  |
|   | 251  | 251   |  |  |
| outstanding as of December 31, 2023 and June 30, 2023, respectively   | 351  | 351   |  |  |
| Series H preferred stock, \$0.01 par value, 15,002 shares authorized, issued and  | 1 50   | 1.50  |  |  |
| outstanding og at Dagamban (1 101) and bing (1) 1001 and signal (1)   | 150  | 150   |  |  |
| outstanding as of December 31, 2023 and June 30, 2023, respectively   |  | 100   |  |  |
| Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding   | 100  | 100   |  |  |
| Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively  | 100  | 100   |  |  |
| Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding<br>as of both December 31, 2023 and June 30, 2023, respectively<br>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and  |  |   |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> </ul>  | 100<br>50  | 50  |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139</li> </ul>   | 50   | 50  |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> </ul>  | 50<br>471,443  | 50<br>443,478   |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> </ul>   | 50<br>471,443<br>128,925   | 50<br>443,478<br>192,925  |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> <li>Additional paid-in capital</li> </ul>   | 50<br>471,443  | 50<br>443,478   |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> </ul>   | 50<br>471,443<br>128,925   | 50<br>443,478<br>192,925  |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> <li>Additional paid-in capital</li> </ul>   | 50<br>471,443<br>128,925<br>148,335,488  | 50<br>443,478<br>192,925<br>145,251,822   |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> <li>Additional paid-in capital</li> <li>Accumulated deficit</li> </ul>  | 50<br>471,443<br>128,925<br>148,335,488<br>(151,951,449)                           | 50<br>443,478<br>192,925<br>145,251,822<br>(141,729,009)                          |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> <li>Additional paid-in capital</li> <li>Accumulated deficit</li> <li>Accumulated other comprehensive loss</li> </ul>  | 50<br>471,443<br>128,925<br>148,335,488<br>(151,951,449)<br>(4,666)                | 50<br>443,478<br>192,925<br>145,251,822<br>(141,729,009)<br>(50,848)              |  |  |
| <ul> <li>Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively</li> <li>Common stock to be issued</li> <li>Additional paid-in capital</li> <li>Accumulated deficit</li> <li>Accumulated other comprehensive loss</li> <li>Total Dalrada Financial Corp's stockholders' equity</li> </ul> | 50<br>471,443<br>128,925<br>148,335,488<br>(151,951,449)<br>(4,666)<br>(3,019,608) | 50<br>443,478<br>192,925<br>145,251,822<br>(141,729,009)<br>(50,848)<br>4,109,019 |  |  |











# **Transformative Innovations.**



Publicly traded on the OTC:QB under the symbol "\$**DFCO**"



# in y f

San Diego Office 600 La Terraza Blvd. Escondido, CA 92025

Phone: 858.283.1253 Email: DFCOinquiries@dalrada.com Website: Dalrada.com





